For BIO, All Roads Lead To India; World Class R&D Apt For Deals But Lack Of Data Protection Create Reticence
This article was originally published in PharmAsia News
You may also be interested in...
Faced With Criticism, Bayh Dole-like Act "At Bay" In India; Government Takes Up Closer Scrutiny (Part 2 of 2)
MUMBAI - Patenting of public-funded research for innovation is now pending scrutiny by India's Parliamentary Standing Committee and has created a deep divide among the rank and file of the Indian pharmaceutical industry. Part one of this story questioned whether such a bill could logistically fit with India's present regulatory structure. In this second part, PharmAsia News interviews different sources on both sides of the divide on this Indian version of the Bayh-Dole Act in the U.S
Jim Greenwood Says BIO Welcomes Biosimilars; Clarity On Non-inferiority Trials For Substitutability Of Biotech Drugs May Come Up Next Year
MUMBAI - The entry of biosimilars into the U.S. market will be welcomed by the biotech industry, Jim Greenwood, CEO of the Biotechnology Industry Organization, which represents multinational biotech companies, told the recent BioInvest conference in Mumbai
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).